Investigational drug · Phase 3
IRP101
Also called: meta-fluorobenzylguanidine, 18F-MFBG, 18F-mFBG for administration, 18F-metaFluorobenzylguanidine
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Cardiovascular Diseases, Heart Failure, Ischemic Cardiomyopathy.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
3
Any phase or sponsor naming "IRP101"
First trial start
2021
Nov 5, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IRP101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cardiovascular Diseases
- Heart Failure
- Ischemic Cardiomyopathy
- ICD Patients
- Parkinson Disease (PD)
- Lewy Body Dementia (LBD)
- Neuroblastoma
Approved drugs for the same conditions: Heart failure · Parkinson's disease · Cardiovascular and metabolic · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "IRP101" as an intervention, largest first.
- Open-Label Study of 18F-mFBG for Imaging NeuroblastomaPivotal-lookingCompleted
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Industry
NCT04724369 · 43 participants · Start Nov 18, 2021 · Primary completion Jul 30, 2026
Drug: 18F-MFBG · For: Neuroblastoma
Sites: Los Angeles, California; San Francisco, California; Indianapolis, Indiana · 8 sites in all
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Industry
NCT06965621 · 20 participants (planned) · Start Nov 5, 2025 · Primary completion Mar 30, 2027
Drug: 18F-metaFluorobenzylguanidine; Rubidium-82 · For: Heart Failure; Ischemic Cardiomyopathy; ICD Patients
Sites: Houston, Texas
- Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic InnervationActive, not recruiting
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Industry
NCT04535193 · 10 participants · Start Nov 5, 2021 · Primary completion Mar 7, 2025
Drug: 18F-mFBG for intravenous administration · For: Cardiovascular Diseases
Sites: New York, New York
Newest research
PubMed records naming it or its code names, newest first.
- Detecting Isolated Multifocal Leptomeningeal Metastases With 18F-MFBG PET/CT in a Pediatric Patient With High-risk Neuroblastoma.
Shi Z, Zheng L, Zhang K, et al. · Clin Nucl Med 2026
- Multiple Bone Metastases Exhibiting Exceptionally High 18 F-MFBG Uptake Exceeding Physiological Bladder Activity in a Patient With Neuroblastoma.
Zhang M, Feng J, Zhang K, et al. · Clin Nucl Med 2026
- Intense Focal Renal 18F-MFBG Uptake Attributable to Radiation in a Pediatric Patient With Neuroblastoma.
Zhang K, Zhang B, Wang Y, et al. · Clin Nucl Med 2026
- Unconfirmed Linear 18F-MFBG Uptake Along the Spinal Canal in a Pediatric Patient With Neuroblastoma: A Potential Diagnostic Pitfall.
Wang Y, Wan Q, Zhang K, et al. · Clin Nucl Med 2026
- Physiological Uterine Uptake of 18F-MFBG During Menstruation in a Pediatric Patient With Neuroblastoma.
Wang X, Pan J, Zhang K, et al. · Clin Nucl Med 2026
- 18F-mFBG PET Detects Neuroblastoma Recurrence Prior to 123I-mIBG SPECT.
Modak S, Behr G, Jacobson AF, et al. · J Pediatr Hematol Oncol 2026
Also in development for Cardiovascular Diseases
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- LepodisiranLY3819469Phase 32 trials
Eli Lilly · Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- MosliciguatPhase 32 trials
Pulmovant, Inc. · Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases
- RalinepagAPD811Phase 32 trials
United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- StromaForteHuman Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product, MSCsPhase 25 trials
Cellcolabs Clinical LTD. · Cardiovascular Diseases, Frailty, Musculoskeletal Injury
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- SPC 2002Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension, Essential, Cardiovascular Diseases, Cardiology
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.